Drugs / NIDO-361
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06411912 | Mar 2024 → Oct 2025 | Kennedy disease, bulbospinal muscular atrophy | Nido Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIDO-361 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06411912 ↗ |
| Route | Oral | “for oral administration” NCT06411912 ↗ |